1 Department of Clinical Medicine - The Danish Pain Research Center, Department of Clinical Medicine, Health, Aarhus University2 Department of Clinical Medicine - The Department of Neurology, Department of Clinical Medicine, Health, Aarhus University3 Department of Neurology, Odense University Hospital, Odense, Denmark. Electronic address: email@example.com Department of Pain Medicine, Bergmannsheil Hospital, Ruhr-University Bochum, Bochum, Germany.5 Department of Pain Medicine, Bergmannsheil Hospital, Ruhr-University Bochum, Bochum, Germany.6 Lundbeck A/S, Copenhagen, Denmark; Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden.7 Department of Neurology, Odense University Hospital, Odense, Denmark.8 Department of Clinical Medicine - The Danish Pain Research Center, Department of Clinical Medicine, Health, Aarhus University
A randomised, double-blind, placebo-controlled phenotype-stratified study
In neuropathic pain it has been suggested that pain phenotype based on putative pain mechanisms may predict response to treatment. This was a randomised, double-blind, placebo-controlled, and phenotype-stratified study with 2 6-week treatment periods of oxcarbazepine (1800-2400mg) and placebo. The primary efficacy measure was change in median pain intensity between baseline and the last week of treatment measured on an 11-point numeric rating scale, and the primary objective was to compare the effect of oxcarbazepine in patients with and without the irritable nociceptor phenotype as defined by hypersensitivity and preserved small nerve fibre function determined by detailed quantitative sensory testing. Ninety-seven patients with peripheral neuropathic pain due to polyneuropathy, surgical or traumatic nerve injury, or postherpetic neuralgia were randomised. The intention-to-treat population comprised 83 patients: 31 with the irritable and 52 with the nonirritable nociceptor phenotype. In the total sample, oxcarbazepine relieved pain of 0.7 points (on a numeric rating scale 0-10; 95% confidence interval [CI] 0.4-1.4) more than placebo (P=0.015) and there was a significant interaction between treatment and phenotype of 0.7 (95% CI 0.01-1.4, P=0.047). The number needed to treat to obtain one patient with more than 50% pain relief was 6.9 (95% CI 4.2-22) in the total sample, 3.9 (95% CI 2.3-12) in the irritable, and 13 (95% CI 5.3-∞) in the nonirritable nociceptor phenotype. In conclusion, oxcarbazepine is more efficacious for relief of peripheral neuropathic pain in patients with the irritable vs the nonirritable nociceptor phenotype.